20250ACR_009997CHP INTRODUCED 2025-06-16 PASSED_ASSEMBLY 2025-06-27 PASSED_SENATE 2025-07-17 ENROLLED 2025-07-21 CHAPTERED 2025-07-24 FILED 2025-07-24 2025 ACR CHP CHR 0 Introduced by Assembly Member Davies (Coauthors: Assembly Members Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Arambula, Ávila Farías, Bains, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Chen, Connolly, DeMaio, Dixon, Elhawary, Ellis, Fong, Gabriel, Gallagher, Garcia, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Kalra, Krell, Lackey, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Rivas, Celeste Rodriguez, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Tangipa, Valencia, Wallis, Wicks, Wilson, and Zbur) LEAD_AUTHOR ASSEMBLY Davies COAUTHOR ASSEMBLY Addis COAUTHOR ASSEMBLY Aguiar-Curry COAUTHOR ASSEMBLY Ahrens COAUTHOR ASSEMBLY Alanis COAUTHOR ASSEMBLY Alvarez COAUTHOR ASSEMBLY Arambula COAUTHOR ASSEMBLY Ávila Farías COAUTHOR ASSEMBLY Bains COAUTHOR ASSEMBLY Bennett COAUTHOR ASSEMBLY Berman COAUTHOR ASSEMBLY Boerner COAUTHOR ASSEMBLY Bonta COAUTHOR ASSEMBLY Bryan COAUTHOR ASSEMBLY Calderon COAUTHOR ASSEMBLY Caloza COAUTHOR ASSEMBLY Carrillo COAUTHOR ASSEMBLY Castillo COAUTHOR ASSEMBLY Chen COAUTHOR ASSEMBLY Connolly COAUTHOR ASSEMBLY DeMaio COAUTHOR ASSEMBLY Dixon COAUTHOR ASSEMBLY Elhawary COAUTHOR ASSEMBLY Ellis COAUTHOR ASSEMBLY Fong COAUTHOR ASSEMBLY Gabriel COAUTHOR ASSEMBLY Gallagher COAUTHOR ASSEMBLY Garcia COAUTHOR ASSEMBLY Gipson COAUTHOR ASSEMBLY Jeff Gonzalez COAUTHOR ASSEMBLY Mark González COAUTHOR ASSEMBLY Hadwick COAUTHOR ASSEMBLY Haney COAUTHOR ASSEMBLY Harabedian COAUTHOR ASSEMBLY Hart COAUTHOR ASSEMBLY Hoover COAUTHOR ASSEMBLY Irwin COAUTHOR ASSEMBLY Jackson COAUTHOR ASSEMBLY Kalra COAUTHOR ASSEMBLY Krell COAUTHOR ASSEMBLY Lackey COAUTHOR ASSEMBLY Lowenthal COAUTHOR ASSEMBLY Macedo COAUTHOR ASSEMBLY McKinnor COAUTHOR ASSEMBLY Muratsuchi COAUTHOR ASSEMBLY Nguyen COAUTHOR ASSEMBLY Ortega COAUTHOR ASSEMBLY Pacheco COAUTHOR ASSEMBLY Papan COAUTHOR ASSEMBLY Patel COAUTHOR ASSEMBLY Patterson COAUTHOR ASSEMBLY Petrie-Norris COAUTHOR ASSEMBLY Quirk-Silva COAUTHOR ASSEMBLY Ramos COAUTHOR ASSEMBLY Ransom COAUTHOR ASSEMBLY Rivas COAUTHOR ASSEMBLY Celeste Rodriguez COAUTHOR ASSEMBLY Michelle Rodriguez COAUTHOR ASSEMBLY Rogers COAUTHOR ASSEMBLY Blanca Rubio COAUTHOR ASSEMBLY Sanchez COAUTHOR ASSEMBLY Schiavo COAUTHOR ASSEMBLY Schultz COAUTHOR ASSEMBLY Sharp-Collins COAUTHOR ASSEMBLY Solache COAUTHOR ASSEMBLY Soria COAUTHOR ASSEMBLY Stefani COAUTHOR ASSEMBLY Ta COAUTHOR ASSEMBLY Tangipa COAUTHOR ASSEMBLY Valencia COAUTHOR ASSEMBLY Wallis COAUTHOR ASSEMBLY Wicks COAUTHOR ASSEMBLY Wilson COAUTHOR ASSEMBLY Zbur Relative to Scleroderma Awareness Day.

Scleroderma Awareness Day Scleroderma Awareness Day. This measure would declare June 29, 2025, as Scleroderma Awareness Day in California. NO

WHEREAS, Scleroderma is a chronic, systemic autoimmune disease primarily characterized by the hardening of the skin, its hallmark symptom, but its impact can extend far beyond the skin to involve internal organs, which can lead to severe complications; and

WHEREAS, Scleroderma is distinguished into two main types: localized scleroderma, which mainly affects the skin, and systemic sclerosis, which can affect large areas of skin and vital organs, including the heart, lungs, kidneys, and gastrointestinal tract; and

WHEREAS, The exact causes of scleroderma remain unclear, but it is thought to arise from a combination of genetic and environmental factors, leading to an overproduction of collagen; and

WHEREAS, Statistically, scleroderma affects approximately 300,000 Americans, of which percent are women who are usually between the ages of and 50, although it can manifest at any age; and

WHEREAS, The diversity in symptoms and severity makes scleroderma a particularly challenging disease to diagnose and manage, often requiring a multidisciplinary approach to treatment that includes rheumatologists, dermatologists, and other specialists; and

WHEREAS, The impact of scleroderma is profound due to the progressive nature of the disease and its effect on multiple body systems; and

WHEREAS, The psychological and socio-economic impacts of scleroderma on patients and their families are considerable, affecting quality of life and daily functioning; and

WHEREAS, In the State of California, recognizing the need for increased awareness and support for scleroderma is crucial; and

WHEREAS, The Scleroderma Foundation of California funds education and awareness programs with a mission to empower the scleroderma community to live their best lives through programs dedicated to support, education, and research; and

WHEREAS, The establishment of Scleroderma Awareness Day aims to enhance public understanding of the disease, promote early diagnosis and treatment, and mobilize community resources and support for those affected;

now, therefore,

be it Resolved by the Assembly of the State of California, the Senate thereof concurring, That the Legislature hereby declares June 29, 2025, as Scleroderma Awareness Day in California, acknowledges the significant challenges faced by individuals living with scleroderma, and affirms the state’s support for medical research and advocacy efforts aimed at combating this debilitating disease; and be it further Resolved, That the declaration of June 29, 2025, as Scleroderma Awareness Day in California reflects the state’s commitment to public health and the well-being of its constituents; and be it further Resolved, That the Chief Clerk of the Assembly transmit copies of this resolution to the author for appropriate distribution.